NovaBay Pharmaceuticals Inc. (AMEX: NBY) is 29.93% higher on its value in year-to-date trading and has touched a low of $0.24 and a high of $1.94 in the current 52-week trading range. The NBY stock was last observed hovering at around $1.05 in the last trading session, with the day’s loss setting it -0.14% off its average median price target of $2.63 for the next 12 months. It is also 74.0% off the consensus price target high of $3.50 offered by 2 analysts, but current levels are 48.0% higher than the price target low of $1.75 for the same period.
Even if you’re not actively in crypto, you deserve to know what’s actually going on...
Because while leading assets such as Bitcoin (BTC) and Ethereum (ETH) are climbing in value, a select group of public “crypto stocks” are surging right along with them. More importantly, these stocks are outpacing the returns these leading crypto assets aren already producing.
Click here to get the full story… along with our long list of backdoor Bitcoin strategies. It’s free. .
Currently trading at $0.91, the stock is 24.82% and 37.48% above its SMA20 and SMA50 respectively. However, with a daily trading volume of 7.88 million and changing -13.75% at the moment leaves the stock 4.68% off its SMA200. NBY registered 49.98% gain for a year compared to 6-month loss of -29.80%. The firm has a 50-day simple moving average (SMA 50) of $0.6952 and a 200-day simple moving average (SMA200) of $0.8482.
The stock witnessed a 31.25% gain in the last 1 month and extending the period to 3 months gives it a 18.07%, and is 23.53% up over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 12.85% over the week and 9.65% over the month.
NovaBay Pharmaceuticals Inc. (NBY) has around 28 employees, a market worth around $37.21M and $9.80M in sales. Distance from 52-week low is 277.33% and -53.32% from its 52-week high. The company has generated returns on investments over the last 12 months (-261.30%).
NovaBay Pharmaceuticals Inc. (NBY) Analyst Forecasts
Analyst recommendations provided by FactSet shows that the consensus forecast for NovaBay Pharmaceuticals Inc. (NBY) is a “Buy”. 2 analysts offering their recommendations for the stock have an average rating of 1.50, where 0 rate it as a Hold and 0 think it is a “Overweight”. 2 of the analysts rate the stock as a “Buy”. 0 analysts have rated the stock as a Sell or Underperform.
NovaBay Pharmaceuticals Inc. is expected to release its quarterly report on 05/13/2021 and quarterly earnings per share for the current quarter are estimated at -$0.04 with sales reaching $2.48M over the same period.The EPS is expected to shrink by -25.30% this year, but quarterly earnings will post 59.10% year-over-year. Quarterly sales are estimated to grow 45.50% in year-over-year returns.
NovaBay Pharmaceuticals Inc. (NBY) Top Institutional Holders
26 institutions hold shares in NovaBay Pharmaceuticals Inc. (NBY), with 10.53M shares held by insiders accounting for 25.21% while institutional investors hold 8.30% of the company’s shares. The shares outstanding are 40.04M, and float is at 31.25M with Short Float at 4.22%. Institutions hold 6.20% of the Float.
The top institutional shareholder in the company is Renaissance Technologies, LLC with over 0.61 million shares valued at $0.45 million. The investor’s holdings represent 1.47% of the NBY Shares outstanding. As of Sep 29, 2020, the second largest holder is Vanguard Group, Inc. (The) with 0.15 million shares valued at $0.11 million to account for 0.36% of the shares outstanding. The other top investors are Geode Capital Management, LLC which holds 70444.0 shares representing 0.17% and valued at over $51424.0, while Virtu Financial LLC holds 0.11% of the shares totaling 46903.0 with a market value of $34239.0.
NovaBay Pharmaceuticals Inc. (NBY) Insider Activity
A total of 2 insider transactions have happened at NovaBay Pharmaceuticals Inc. (NBY) in the last six months, with sales accounting for 1 and purchases happening 1 times. The most recent transaction is an insider sale by WU MIJIA, the company’s Director. SEC filings show that WU MIJIA sold 20,000 shares of the company’s common stock on Aug 17 at a price of $1.35 per share for a total of $27000.0. Following the sale, the insider now owns 0.0 shares.
NovaBay Pharmaceuticals Inc. disclosed in a document filed with the SEC on Aug 01 that Fu Jian Ping (10% Owner) sold a total of 1,302,350 shares of the company’s common stock. The trade occurred on Aug 01 and was made at $1.23 per share for $1.6 million. Following the transaction, the insider now directly holds 4.0 million shares of the NBY stock.
NovaBay Pharmaceuticals Inc. (NBY): Who are the competitors?
The company’s main competitors (and peers) include SIGA Technologies Inc. (SIGA) that is trading 43.22% up over the past 12 months. Short interest in the company’s stock has fallen -17.65% from the last report on Nov 29, 2020 to stand at a total of 1.2 million short shares sold with a short interest ratio of 0.52.